Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

Phase 2

Recruiting

• Conditions: Waldenstrom Macroglobulinemia
• Interventions: Drug: Rituximab, ibrutinib; Drug: Dexamethasone, cyclophosphamide, rituximab

• Registration Number: NCT04061512
• Lead Sponsor: University College, London

Brief Summary

Waldenström's macroglobulinaemia (WM) is a rare type of slow growing lymphoma. It develops when white blood cells grow abnormally.

Typically a disease of the elderly, the median age of presentation is \>70 years and the current treatment for WM is unsatisfactory, with incomplete responses and inevitable recurrence. Therefore there is a need to find alternative treatments that are more effective, leading to lasting responses and improved quality of life.

The RAINBOW study is a phase 2-3 trial assessing 'chemotherapy free' treatment as primary therapy for WM which can potentially improve response outcome, durability and importantly, reduce toxicity for WM patients. This approach will be done using the drug Ibrutinib, which in combination with rituximab (RI) will be the experimental arm. As there is no agreed standard on first-line therapy for WM, the control arm is the current treatment based on the most recently published clinical trial results. The control arm consists of rituximab, cyclophosphamide and dexamethasone (DCR), and is widely recommended by international consensus as appropriate treatment for first-line therapy for WM.

In this study, 148 adults (aged ≥ 18 years) with treatment naïve WM will be randomised on a 1:1 ratio to either the treatment or control arm.

Randomised treatment lasts for a maximum of 6 cycles and response will be assessed following 3 cycles of treatment and completion of randomised treatment at approximately 24 weeks after commencing treatment. RI patients may then have up to 5 years of Ibrutinib monotherapy.

Patients will be seen regularly during treatment and then every 3 months for 5 years after treatment discontinuation. Patients will enter annual follow up for survival until the end of trial (including progressed patients).

The study will be conducted at NHS hospitals and is expected to last 9 years and 6 months.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-07-01
• Study First Submitted QC: 2019-08-16
• Study First Posted: 2019-08-19
• Study Start: 2020-02-03
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-09
• Last Update Posted: 2024-05-10
• Primary Completion: 2030-03
• Study Completion: 2030-03

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 148

Inclusion Criteria

1. Patients ≥ 18 years

2. Confirmed diagnosis of WM (according to consensus panel / WHO criteria) with measurable IgM paraprotein

3. Previously untreated disease at any stage requiring therapy at the discretion of the treating physician. Suggested criteria for initiating treatment include:

   • haematological suppression to Hb <10g/dl, or neutrophils <1.5x109/l or platelets <150x109/l
   • clinical evidence of hyperviscosity
   • bulky lymphadenopathy and/or bulky splenomegaly
   • presence of B symptoms

4. No previous chemotherapy (prior plasma exchange and steroids are permissible)

5. Eastern Cooperative Oncology Group (ECOG) performance status grade 0 - 2

6. Life expectancy of greater than 6 months

7. Written informed consent

8. Willing to comply with the contraceptive requirements of the trial

9. Negative serum or urine pregnancy test for women of childbearing potential (WOCBP)

Read More

Exclusion Criteria

1. Prior therapy for WM

2. Lymphoplasmacytic lymphoma with no detectable serum IgM paraprotein

3. CNS involvement with WM

4. Autoimmune cytopenias

5. Major surgery within 4 weeks prior to randomisation

6. Clinically significant cardiac disease including the following:

   • Myocardial infarction within 6 months prior to randomisation
   • Unstable angina within 3 months prior to randomisation
   • New York Heart Association class III or IV congestive heart failure
   • History of clinically significant arrhythmias (e.g. sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes)
   • QTcF > 480 msecs based on Fredericia's formula or Bazette's formula
   • History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place
   • Uncontrolled hypertension as indicated by a minimum of 2 consecutive blood pressure measurements showing systolic blood pressure > 170 mmHg and diastolic blood pressure > 105 mm Hg
   • Cardiac event within 6 months of screening (e.g. coronary artery stent) requiring dual antiplatelet treatment

7. History of stroke or intracranial haemorrhage within 6 months prior to randomisation

8. Requires anticoagulation with warfarin or equivalent vitamin K antagonists (direct oral anticoagulants (DOACs) allowed)

9. History of severe bleeding disorders considered not to be disease related (Haemophilia A, B or von Willebrand's disease)

10. Requires ongoing treatment with a strong CYP3A inhibitor or inducer

11. Known infection with HIV, or serologic status reflecting active hepatitis B or C infection as follows:

    • Presence of hepatitis B surface antigen (HBsAg). In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the patient will be excluded
    • Presence of hepatitis C virus (HCV) antibody. Patients with presence of HCV antibody are eligible if HCV RNA is undetectable

12. Women who are pregnant or breastfeeding or males expecting to conceive or father children at any point from the start of treatment until the end of the "at risk period"

13. Renal failure (creatinine clearance <30 ml/min as estimated by the Cockroft-Gault equation)

14. Patients with chronic liver disease with hepatic impairment Child-Pugh class B or C

15. Known history of anaphylaxis following exposure to rat or mouse derived CDR-grafted humanised monoclonal antibodies.

16. Inability to swallow oral medication

17. Disease significantly affecting gastrointestinal function and/or inhibiting small intestine absorption (e.g. malabsorption syndrome, resection of the small bowel, poorly controlled inflammatory bowel disease)

18. Active systemic infection requiring treatment

19. Concomitant treatment with another investigational agent

20. Any life-threatening illness, medical condition, organ system dysfunction, need for profound anticoagulation, or bleeding disorder, which, in the investigator's opinion, could compromise the patient's safety, or put the study at risk

21. Unwilling or unable to take PCP prophylaxis (e.g. cotrimoxazole)

22. History of prior malignancy, with the exception of the following:

    • Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to screening and felt to be at low risk for recurrence by treating physician
    • Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma, superficial bladder cancer, carcinoma in situ of the cervix or breast or localized Gleason score 6 prostate cancer without current evidence of disease.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
RI Arm	Rituximab, ibrutinib	The RI arm (chemotherapy free) arm will be using the drug ibrutinib, which in combination with rituximab (RI) will be the experimental arm.
DRC Arm	Dexamethasone, cyclophosphamide, rituximab	The DRC arm (chemotherapy) is the control arm and consists of rituximab, cyclophosphamide and dexamethasone. It is widely recommended by international consensus as appropriate treatment for first-line therapy for WM.

Primary Outcome Measures

Name	Time	Method
Percentage of patients achieving a preliminary efficacy (response) of the 'chemotherapy free' combination of rituximab and ibrutinib (RI) as primary therapy for WM.	Overall response rate at week 24
Progression free survival (PFS) analysis of rituximab/ibrutinib (RI) when compared to dexamethasone/rituximab/cyclophosphamide (DRC) at 2 years after the last randomisation	2 years after the last randomisation

Secondary Outcome Measures

Name	Time	Method
Safety and tolerability of RI compared to DRC assessed by the frequency of serious and non-serious adverse events according to CTCAE v5.0	until 30 calendar days post last IMP administration
Overall response rate (defined as complete response [CR], very good partial response [VGPR], partial response [PR] and minor response [MR]) of RI compared to DRC (at end of randomised treatment and best response over any time point)	through study completion, an average of 2 years.
Time to next treatment	through study completion, an average of 2 years.
Duration of response of RI compared to DRC	through study completion, an average of 2 years.	(responding patients only)
Overall survival (OS) of patients treated with RI compared to DRC	date of randomisation until the date of death (of any cause)
Quality of Life:EQ-5D-5L questionnaire	1 year and 2 years after completion of randomised treatment against the baseline quality of life score	Change in quality of life (QoL) responses in each arm assessed by EQ-5D-5L questionnaire

Trial Locations

Locations (25)

The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust; 🇬🇧 Bournemouth, United Kingdom

University Hospital of Wales; 🇬🇧 Cardiff, United Kingdom

Royal United Hospital, Bath; 🇬🇧 Bath, United Kingdom

NHS Lanarkshire; 🇬🇧 Lanark, United Kingdom

Royal Devon University Hospital; 🇬🇧 Exeter, United Kingdom

King's College Hospital; 🇬🇧 London, United Kingdom

Medway Maritime Hospital; 🇬🇧 Gillingham, United Kingdom

Barking, Havering and Redbridge University Hospitals NHS Trust; 🇬🇧 London, United Kingdom

Barts Health NHS Trust; 🇬🇧 London, United Kingdom

Northwick Park Hospital; 🇬🇧 London, United Kingdom

Norfolk and Norwich Hospital; 🇬🇧 Norwich, United Kingdom

Salisbury NHS Foundation Trust; 🇬🇧 Salisbury, United Kingdom

Torbay & Newton Abbot Hospital; 🇬🇧 Torquay, United Kingdom

University Hospitals Plymouth NHS Trust; 🇬🇧 Plymouth, United Kingdom

Royal Cornwall Hospital; 🇬🇧 Truro, United Kingdom

Colchester Hospital; 🇬🇧 Colchester, United Kingdom

Mid Yorkshire NHS Trust; 🇬🇧 Dewsbury, United Kingdom

St James's University Hospital; 🇬🇧 Leeds, United Kingdom

Leicester Royal Infirmary; 🇬🇧 Leicester, United Kingdom

Hampshire Hospitals NHS Foundation Trust; 🇬🇧 Winchester, United Kingdom

Christie NHS Foundation Trust; 🇬🇧 Manchester, United Kingdom

Oxford University Hospital; 🇬🇧 Oxford, United Kingdom

University College London Hospitals NHS Foundation Trust; 🇬🇧 London, United Kingdom

East Kent Hospitals University NHS Foundation Trust; 🇬🇧 Canterbury, United Kingdom

Castle Hill Hospital; 🇬🇧 Hull, United Kingdom